From Financialisation to Innovation in UK Big Pharma(Elements in Reinventing Capitalism)

从金融化到英国大型制药公司的创新:阿斯利康、葛兰素史克

管理思想史

售   价:
169.00
发货周期:通常付款后3-5周到货!
作      者
出  版 社
出版时间
2022年12月31日
装      帧
平装
ISBN
9781009278164
复制
页      码
75
开      本
229x152mm
语      种
英文
综合评分
暂无评分
我 要 买
- +
库存 30 本
  • 图书详情
  • 目次
  • 买家须知
  • 书评(0)
  • 权威书评(0)
图书简介
The tension between innovation and financialisation is central to the business corporation. Innovation entails a ’retain-and-reinvest’ allocation regime that can form a foundation for stable and equitable economic growth. Driven by shareholder-value ideology, financialisation entails a shift to ’downsize-and-distribute’. This Element investigates this tension in global pharmaceuticals, focusing on the two leading UK companies AstraZeneca and GlaxoSmithKline. In the 2000s both adopted US-style governance, including stock buybacks and stock-based executive pay. Over the past decade, however, first AstraZeneca and then GlaxoSmithKline transitioned to innovation. Critical was the cessation of buybacks to refocus capabilities on investing in an innovative drugs pipeline. Enabling this shift were UK corporate-governance institutions that mitigated US-style shareholder-value maximisation. Reinventing capitalism for the sake of stable and equitable economic growth means eliminating value destruction caused by financialisation and supporting value creation through collective and cumulative innovation. This title is also available as Open Access on Cambridge Core.
本书暂无推荐
本书暂无推荐
看了又看
  • 上一个
  • 下一个